MetaCap

Achieve Life Sciences Inc. (QUIT)

NASDAQ: QUITHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

5.56-0.31 (-5.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QUIT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$573.25M
EPS (TTM)
-$1.71
52-week range
2.62 – 8.64
Day range
5.50 – 5.97
Volume / Avg
1.92M / 1.38M
Beta
—
Next earnings
Nov 26, 2026

52-week range

$2.62$8.64

QUIT stock today

On Nov 20, QUIT ended the session at $5.56, shedding $0.31 (5.28%), versus the S&P 500's 3.70% decline. Shares are 35.6% below their 52-week high of $8.64, set on Sep 3, 2026 and 112.2% above the 52-week low of $2.62, in the middle of the past year's range. Achieve Life Sciences has posted a net loss over the last twelve months (EPS of -$1.71), so its P/E ratio is not meaningful.

The company is scheduled to report Sep/2026 results on Nov 26; analysts expect EPS of -$0.19.

Summary generated from market data by MetaCap's automated system. Methodology

About Achieve Life Sciences

Company profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Dr. Andrew D. Goldberg M.D.
Headquarters
Bothell, WA
Employees
28

Financial highlights

Full financials

Achieve Life Sciences reported a net loss of $54.6 million, compared with a loss of $39.8 million a year earlier. Diluted earnings per share came in at -$1.25.

Achieve Life Sciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-54.65M$-39.83M$-29.82M$-42.35M$-33.15M
EPS (diluted)$-1.25$-1.24$-1.50$-4.00$-4.08

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$14.58+162.23%

  • Strong buy 3
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 26, 2026
EPS estimate
$-0.19
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.28 vs $-0.19
Surprise
-47.37%

QUIT news

All QUIT news

Achieve Life Sciences peers

Health Care sector
QUIT peer companies
CompanyPrice% ChgMarket capCompare
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs QUIT
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs QUIT
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs QUIT
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs QUIT
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs QUIT
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs QUIT
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs QUIT
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs QUIT

Indexes, lists and sector

Achieve Life Sciences stock FAQ

What is Achieve Life Sciences's stock price today?

QUIT last traded at $5.56 as of Nov 20, 4:00 PM EST, down 5.28% on the day. Prices are delayed at least 15 minutes.

When is Achieve Life Sciences's next earnings date?

Achieve Life Sciences is expected to report earnings on Thursday, November 26, 2026. Analysts expect EPS of $-0.19.

Who is Achieve Life Sciences's CEO?

Dr. Andrew D. Goldberg M.D. is the chief executive officer of Achieve Life Sciences Inc., which has about 28 employees.

What is the QUIT 52-week high?

The 52-week high for QUIT is $8.64 and the 52-week low is $2.62. The stock is currently 35.6% below its high.

Compare QUIT